Abstract:BackgroundThe efficacy of B cell-depleting therapies for rheumatoid arthritis underscores antibody-independent functions of effector B cells such as cognate T–B interactions and production of pro-inflammatory cytokines. Receptor activator of nuclear factor κB ligand (RANKL) is a key cytokine involved in bone destruction and is highly expressed in synovial fluid B cells in patients with rheumatoid arthritis. In this study we sought to clarify the generation mechanism of RANKL+ effector B cells and their impacts on osteoclast differentiation.MethodsPeripheral blood and synovial fluid B cells from healthy controls and patients with rheumatoid arthritis were isolated using cell sorter. mRNA expression of RANKL, osteoprotegerin, tumor necrosis factor (TNF)-α, and Blimp-1 was analyzed by quantitative real-time polymerase chain reaction. Levels of RANKL, CD80, CD86, and CXCR3 were analyzed using flow cytometry. Functional analysis of osteoclastogenesis was carried out in the co-culture system using macrophage RAW264 reporter cells.ResultsRANKL expression was accentuated in CD80+CD86+ B cells, a highly activated B-cell subset more abundantly observed in patients with rheumatoid arthritis. Upon activation via B-cell receptor and CD40, switched-memory B cells predominantly expressed RANKL, which was further augmented by interferon-γ (IFN-γ) but suppressed by interleukin-21.Strikingly, IFN-γ also enhanced TNF-α expression, while it strongly suppressed osteoprotegerin expression in B cells. IFN-γ increased the generation of CXCR3+RANKL+ effector B cells, mimicking the synovial B cell phenotype in patients with rheumatoid arthritis. Finally, RANKL+ effector B cells in concert with TNF-α facilitated osteoclast differentiation in vitro.ConclusionsOur current findings have shed light on the generation mechanism of pathogenic RANKL+ effector B cells that would be an ideal therapeutic target for rheumatoid arthritis in the future.

Targeting the RANK/RANKL pathway in autoimmune disease and malignancy: future perspectives

TNF-family member Receptor Activator of NF-κB (RANK) and RANK-Ligand (RANKL) in bone remodelling

RANKL and RANK as novel therapeutic targets for arthritis

RANKL biology: bone metabolism, the immune system, and beyond

[Role of tumor necrosis factor family ligands in the pathogenesis of rheumatoid arthritis--new therapeutical opportunities]

Generation mechanism of RANKL+ effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis

Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis

Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases

Regulation of T cell-associated tissues and T cell activation by RANKL-RANK-OPG

Targeting the RANKL/RANK/OPG Axis for Cancer Therapy

Signaling crosstalk between RANKL and interferons in osteoclast differentiation

Correlating Rank Ligand/Rank Binding Kinetics with Osteoclast Formation and Function

New Insights for RANKL as a Proinflammatory Modulator in Modeled Inflammatory Arthritis

Targeting RANK/RANKL in the treatment of solid tumours and myeloma

The Roadmap of RANKL/RANK Pathway in Cancer

Discovery of the RANKL/RANK/OPG system

RANKL-stimulated TNFα production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways

The Pathogenetic Role of RANK/RANKL/OPG Signaling in Osteoarthritis and Related Targeted Therapies

Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation

The molecular understanding of osteoclast differentiation

Tumor Necrosis Factor‐α Mediates RANK Ligand Stimulation of Osteoclast Differentiation by an Autocrine Mechanism †